Diaxonhit, Felicitex Therapeutics deal

Diaxonhit granted Felicitex exclusive, worldwide rights to develop and commercialize preclinical small molecule compounds targeting dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK...